Ido T, Wan CN, Casella V, et al. Labeled 2-deoxy-D-glucose analogs: 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose.J Labeled Compounds Radiopharm 1978; 24:174-83.
Reivich M, Kuhl D, Wolf A, et al. The [18F]fluorodeoxy- glucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979;44:127-37.
Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radio- Graphics 2003;23:315-40.
Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154-61.
Hoh K, Howkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using [F-18]fluoro-2-deoxy-D-glu- cose. J Comput Assist Tomogr 1993;17:582-9.
Delbeke D. Oncological Applications of FDG PET imaging. J Nucl Med 1999;40:1706-15.
Fletcher JW, Djulbegovic B, Soares HP, et al. Recommen- dations on the Use of 18F-FDG PET in Oncology. J Nucl Med 2008;49:480-508.
Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radi- ology 2006;238:405-22.
Medicare National Coverage Determinations Manual. Chapter 1, Part 4 (Sections 200-310.1)(Rev. 146, 08-03- 12)Available at http://www.cms.gov/Regulations-and- Guidance/Guidance/Manuals/downloads/ncd103c1_ Part4.pdf[Access December 16, 2012.]
Buck AK, Herrmann K, Stargardt T, et al. Economic Eval- uation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. J Nucl Med Tech 2010;38:6-17.
Review of PET services in Hong Kong hospital author- ity. Part 2—Programming and service rationalization. Release Date June 2012. Available at http://www.ha.org. hk/haho/ho/adm/210576e.pdf[Access December 17, 2012].
The Royal College of Radiologists. PET-CT in the UK, A strategy for development and integration of a leading edge technology within routine practice. 2005; Available at http://www.rcr.ac.uk/docs/general/pdf/PETCT_final. pdf[Access December 17, 2012].
Martinuk SD. The Use of Positron Emission Tomography (PET) for Cancer Care Across Canada Time for a National Strategy. 2011; AAPS, Inc. and TRIUMF.
Funding arrangements for diagnostic imaging services, an international literature review. 2009 Available at https:// www.health.gov.au/internet/main/publishing.nsf/Content/ DA4840C15CF15F0CCA2576D300019741/$File/ ACIL%20TASMAN%20Final%20Report%20-%20 International%20Funding%20Models%20for%20 Diagnostic%20Imaging.pdf[Access December 18, 2012].
International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. St.Louis, MO:2000;49. ICRP publication 80.
Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure Guidline for Tumor Imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
International Atomic Energy Agency (IAEA), Cyclotron Produced Radionuclides: Principles and practice, Technical Reports Series No. 465, IAEA, Vienna, 2008.
International Atomic Energy Agency (IAEA), Cyclotron Produced Radionuclides: Guidelines for setting up a facility, Technical Reports Series No. 471, International Atomic Energy Agency (IAEA), Vienna, 2009.
Jacobson MS, Hung JC, Mays TL, Mullan BP. The plan- ning and design of a new PET radiochemistry facility. Mol Imaging Biol 2002;4:119-27.
IAEA, Cyclotron Produced Radionuclides: Guidance on Facility Design and Production of [18F]Fluorodeoxyglu- cose (FDG), IAEA radioisotopes and radiopharmaceuti- cals series No.3, IAEA, Vienna, 2012.
Stafford RG. Code of Practice for the Design of Laborato- ries using Radioactive Substances for Medical Purposes, Commonwealth of Australia, Australian Government Publishing Service, Canberra 1981; Appendix XVIII.
World Health Organization, Annex 3: Guidelines on Good Manufacturing Practices for Radiopharmaceutical Products, WHO Technical Report Series, No. 908, WHO, Geneva, 2003.
European Union, EudraLex: The Rules Governing Medic- inal Products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use, Annex 3: Manu- facture of Radiopharmaceuticals, Brussels, September, 2008.
US Food and Drug Administration, Department of Health and Human Services, 21 CFR Part 212 Current Good Manufacturing Practice for Positron Emission Tomogra- phy Drugs.
Fowler JS, Ido T. Initial and subsequent approach for the synthesis of 18FDG. Semin Nucl Med 2002;32:6-12.
Levy S, Elmaleh DR, Livni E. A new method using anhydrous [18F]fluoride to radiolabel 2-[18F]fluoro-2- deoxy-D-glucose. J Nucl Med 1982;23:918-22.
Hamacher K, Coenen HH, Stocklin G. Efficient stereo- specific synthesis of no-carrier-added 2-[18F]-fluoro-2- deoxy-D-glucose using aminopolyether supported nucleo- philic substitution. J Nucl Med 1986;27:235-8.
Yu S. Review of 18F-FDG synthesis and quality control.Biomed Imaging Interv J 2006;2:e57.
International Pharmacopoeia, Monograph: Fludeoxyglu- cose (18F) Injection, International Pharmacopoeia, 2008.
European Pharmacopoeia, Monograph: Fludeoxyglucose (18F) Injection, European Pharmacopoeia Ed. 6, 2009.
US Pharmacopoeia, Monograph: Fludeoxyglucose18F Injection, US pharmacopoeia, 2009.
International Atomic Energy Agency (IAEA), Guidelines for Good Manufacturing Practices of Radiopharmaceuticals, IAEA, Vienna, 2001.
The European Pharmacopoeia (Ph.EUR): The European GMP Guidelines for Medicinal Products for Human Use. Annex 1: Manufacture of Sterile Products and Annex 3. Manufacture of Radiopharmaceuticals.
Canadian Health Products and Food Branch Inspectorate, Positron Emitting Radiopharmaceuticals (PER), Annex to the Good Manufacturing Practices (GMP) Guidelines, Guide-0071, February 15, 2006.
